| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 17/04/2023 | 15:10 | Business Wire | AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/04/2023 | 22:05 | Business Wire | AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 06/04/2023 | 22:05 | Business Wire | AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 22/03/2023 | 14:00 | Business Wire | AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease | NASDAQ:ABCL | AbCellera Biologics Inc |
| 14/03/2023 | 21:30 | Business Wire | AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 13/03/2023 | 11:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2023 | 22:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2023 | 22:05 | Business Wire | AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 21/02/2023 | 22:05 | Business Wire | AbCellera Reports Full Year 2022 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 13/02/2023 | 20:50 | Edgar (US Regulatory) | Schedule 13g
(sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 06/02/2023 | 22:32 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 01/02/2023 | 22:05 | Business Wire | AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 24/01/2023 | 22:05 | Business Wire | AbCellera to Report Full Year 2022 Financial Results on February 21, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 20/01/2023 | 01:00 | Business Wire | AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/01/2023 | 22:05 | Business Wire | AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 15/12/2022 | 13:00 | Business Wire | AbCellera and AbbVie Partner to Advance New Antibody Therapies | NASDAQ:ABCL | AbCellera Biologics Inc |
| 01/12/2022 | 20:35 | TipRanks | AbCellera Biologics (ABCL) Gets a Buy from Berenberg Bank | NASDAQ:ABCL | AbCellera Biologics Inc |
| 01/12/2022 | 13:00 | Business Wire | AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases | NASDAQ:ABCL | AbCellera Biologics Inc |
| 10/11/2022 | 14:05 | Business Wire | AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 09/11/2022 | 12:15 | TipRanks | Berenberg Bank Remains a Buy on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 08/11/2022 | 22:05 | Business Wire | AbCellera Reports Q3 2022 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/11/2022 | 21:05 | Business Wire | AbCellera to Present at Upcoming Investor Conferences in November | NASDAQ:ABCL | AbCellera Biologics Inc |
| 02/11/2022 | 20:45 | TipRanks | Berenberg Bank Reaffirms Their Buy Rating on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 02/11/2022 | 14:00 | Business Wire | AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/10/2022 | 22:05 | Business Wire | AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 05/10/2022 | 14:00 | Business Wire | AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 26/09/2022 | 15:50 | TipRanks | Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 21/09/2022 | 14:00 | Business Wire | AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/08/2022 | 05:16 | TipRanks | SVB Securities Reaffirms Their Buy Rating on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 10/08/2022 | 15:35 | TipRanks | BMO Capital Remains a Buy on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |